Minimum effective low dose of antithymocyte globulin in people aged 5–25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial

Journal:
The Lancet
Published:
DOI:
10.1016/s0140-6736(25)01674-5
Affiliations:
30
Authors:
72
Go to article
Institutions Authors Share
Cardiff University, United Kingdom (UK)
4.000000
 0.12
Sanofi-Aventis Deutschland GmbH, Germany
3.000000
 0.09
University Hospitals Leuven (UZ Leuven), Belgium
2.500000
 0.08
University of Copenhagen (UCPH), Denmark
2.333333
 0.07
Auf der Bult Centre for Children and Adolescents, Germany
2.000000
 0.06
University of Cambridge, United Kingdom (UK)
2.000000
 0.06
Catholic University of Leuven (KU Leuven), Belgium
1.500000
 0.05
King's College London (KCL), United Kingdom (UK)
1.500000
 0.05
University of Helsinki, Finland
1.500000
 0.05
IRCCS San Raffaele Hospital (HSR), Italy
1.000000
 0.03
Cambridge University Hospitals NHS Foundation Trust, United Kingdom (UK)
1.000000
 0.03
The Royal London Hospital, United Kingdom (UK)
1.000000
 0.03
Antwerp University Hospital (UZA), UA, Belgium
1.000000
 0.03
Oxford University Hospitals NHS Trust (OUH), United Kingdom (UK)
1.000000
 0.03
Free University of Brussels (VUB), Belgium
1.000000
 0.03
Ljubljana University Medical Centre (Ljubljana UMC), Slovenia
1.000000
 0.03
University of Ljubljana, Slovenia
1.000000
 0.03
Medical University of Vienna (MUW), Austria
1.000000
 0.03
Medical University of Graz (Med Uni Graz), Austria
1.000000
 0.03
Sanofi, France
0.500000
 0.02
Université Libre de Bruxelles (ULB), Belgium
0.500000
 0.02
HUS New Children's Hospital, Finland
0.500000
 0.02
Erasme Hospital, Belgium
0.500000
 0.02
Copenhagen University Hospital (CUH), Denmark
0.333333
 0.01
Steno Diabetes Center Copenhagen (SDCC), Denmark
0.333333
 0.01
Interested in Immunology?